SoftBank Vision Fund 2 co-led a series B round for immunotherapy developer Umoja Biopharma with Cormorant Asset Management.
Umoja Biopharma, the US-based developer of an in vivo immunotherapy platform, completed a $210m series B round co-led by internet and telecommunications group SoftBank’s Vision Fund 2 on Tuesday.
Investment manager Cormorant Asset Management co-led the round, while life sciences real estate investment trust Alexandria Real Estate Equities participated through its Alexandria Venture Investments vehicle.
RTW Investments, Temasek, Apeiron Investment Group’s Presight Capital subsidiary, Caas Capital, MPM Capital, DCVC Bio, Qiming Venture Partners USA, Casdin Capital, Emerson Collective and an…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
